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ABSTRACT
Objective: The objective of the present study is to formulate freeze-dried oral sustained release polymeric nanoparticles of nateglinide (NTG) to 
decrease dosing frequency, increase bioavailability, and minimize side effects.
Methods: NTG-loaded ethyl cellulose (EC) nanoparticles were prepared by solvent evaporation technique and subjected to various studies for 
characterization, such as particle size, zeta potential, drug loading (DL), entrapment efficiency (EE), scanning electron microscopy, and evaluated for 
in vitro drug release.
Results: From this study, it was observed that the fabricated nanoparticles showed satisfactory results, i.e. particle size with 172 nm, 72.19% EE, 
−15.81 mV zeta potential, and 14.30% DL. The results of in vitro release show that sustained release of NTG from the nanoparticles over the period 
of 12 hrs and comparable with the immediate release tablets. Furthermore, accelerated stability studies revealed that the formulation is stable as per 
International Conference on Harmonisation guidelines.
Conclusion: Thus, the nanoparticles formulation could be a promising delivery system for NTG with improved anti-diabetic activity, stability, and 
bioavailability.
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INTRODUCTION
Nanoparticles are an effective formulation for the delivery of 
hydrophobic and hydrophilic drugs, since the drugs are protected from 
possible degradation by enzymes, and it can deliver drugs at a sustained 
rate providing better efficacy and lower toxicity for treatment of various 
diseases [1]. Recently, nanoparticles process have been developed and 
reported for pharmaceutical application to increases the dissolution 
rate of low-soluble drugs which in turn may leads to significantly 
increase in bioavailability and also it is essential for pharmaceutical 
industry as an alternative drug delivery system for the treatment of 
chronic disease like diabetes mellitus [2].
Diabetes mellitus is a metabolic disorder characterized by high blood 
glucose level resulting from inadequate secretion or utilization of 
insulin [3]. Nateglinide (NTG) has been exploited as a new class of an 
oral anti-diabetic agent used in the management of Type 2 diabetes 
mellitus. NTG, (-)-N-[(trans-4-isopropylcyclohexane) carbonyl]-D-
phenylalanine, is structurally (Fig. 1) unrelated to the oral sulfonylurea 
insulin secretagogues. NTG is a D-phenylalanine derivative recently 
approved for the management of Type II diabetes [4,5]. In difference 
to sulfonylureas, NTG increases pancreatic β-cell sensitivity to 
ambient glucose without increasing basal insulin secretion after oral 
administration. It can be used as monotherapy or in combination with 
metformin or thiazolidinedione. It has a short half-life of 1.5 hrs. and 
peak plasma concentration extents at 0.5-1.0 hr. It is metabolized by 
cytochrome P-450 system to an inactive metabolite and eliminated with 
a half-life of 1.4 hrs [6].
The objective of the present study was to formulate and evaluate the 
freeze-dried oral sustained release polymeric nanoparticles of NTG to 




NTG was a gift sample from Glanmark Pharmaceutics Ltd., Mumbai, 
India. Ethyl cellulose (EC) was from Hi-media Laboratories, Mumbai, 
India. Polyvinyl alcohol was from Fourrts India Laboratories Pvt. Ltd., 
Chennai, India. Methanol was from Qualigens Fine Chemicals, Chennai, 
India. All other chemicals used were of analytical reagent grade.
Methods
Preparation of NTG nanoparticles
The NTG-loaded EC nanoparticles were prepared by the solvent 
evaporation method. Briefly, 30 mg of NTG and 150 mg of EC were 
dissolved in 40 ml mixture of methanol and acetone in 1:2 ratio using 
a vortex shaker to form homogeneous organic phase of NTG and EC 
and it was added drop by drop into the 60 ml of 1% aqueous phase 
of polyvinyl alcohol using mechanical stirrer at 1000 rpm for 2 hrs to 
prepare nano-suspension and thoroughly evaporate the organic phase 
followed by magnetic stirring for 2 hrs under atmospheric pressure 
at room temperature. The solution was centrifuged at 15,000 rpm for 
15 minutes and after centrifugation the supernatant was removed and 
the pellets obtained were washed thrice with distilled water and finally 
freeze-dried to get the powdered nanoparticles. The nanoparticles 
were prepared in triplicate to get the reproducibility and reliability. 
Research Article
Fig. 1: Chemical structure of nateglinide
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These nanoparticles were characterized by fixing the experimental 
assay conditions based on the pre-conducted preliminary experimental 
results, carried out in our previous studies [7,8].
Characterization of nanoparticles
Determination of particle size and zeta potential
Particle size of fabricated nanoparticles was measured by particle size 
analyzer (MASTERSIZER 2000, MALVERN Instruments, UK) equipped 
with MAS OPTION particle sizing software. The measurements 
were made at a fixed angle of 90° for all samples. The samples 
were suitably diluted with Milli Q water for every measurement. 
Zeta potential measurements were measured by Malvern zetasizer 
(MAL 1054413 Zetasizer Version 6.20 Instruments, UK). For zeta 
potential determination, samples of all formulations were diluted 
with 0.1 m mol KCl and placed in the electrophoretic cell, where an 
electric field of about 15 V/cm was applied. The mean hydrodynamic 
diameter (Dh) and polydispersity index (PI) of the particles were 
calculated using the cumulative analysis after averaging the three 
measurements [9].
Scanning electron microscopy (SEM)
SEM analysis of the nanoparticles formulation was performed to 
evaluate the surface morphology of nanoparticles. Images were 
taken using JEOL JSM-6701F (Tokyo, Japan) at 3.0 kV with 50,000 
magnifications and 100 nm scale bar was used [10].
Chromatographic conditions
NTG estimation was carried out by reverse phase high pressure 
liquid chromatographic (RP-HPLC) based on the reported method by 
Madhaviet al., 2008 [11]. An isocratic RP-HPLC with Shimadzu LC-20AD 
PLC pump and an SPD-M20A photo diode array detector were used. 
Separation was carried out on a phenomenex C18 column (particle size 
5 μm; 150 × 4.6 mm i.d.) using acetonitrile: 10 mM sodium di-hydrogen 
phosphate (NaH2PO4) buffer solution [phosphate-buffered solution 
(PBS); adjusted to pH 3.0 with H3PO4] in the ratio of 50:50, v/v. The 
flow rate was 1.0 ml/min at 27°C, and the detection was monitored at 
a wavelength of 210 nm. The injection volume was 20 µl. Acetonitrile 
was used as diluent.
Determination of drug loading (DL) and entrapment 
efficiency(EE)
The DL and EE were estimated by RP-HPLC method, following the 
previously described protocol with slight modification [11]. In briefly, 
A 10 mg sample of the formulated nanoparticles was dissolved in 10 ml 
acetonitrile (as common solvent for both the drug and polymer) and 
from the above solution 20 µl was taken for RP-HPLC analysis. The 
amount of drug in the solution was calculated using standard graph of 











×100   (1)
Entrapment efficiency (%)=
Massof drug in nanoparticles
Massof drug added in formulation
×100 (2)
Drug release studies
The in vitro release of marketed formulation and NTG-loaded EC 
nanoparticles were carried out using dialysis bag diffusion method. 
Briefly, 2 mg samples are dispersed in 2 ml of PBS at pH 7.4 and were 
kept in a dialysis bag (cellulose acetate membrane with molecular 
weight cut-off value of 10,000) and tightly closed. The dialysis bag was 
immersed in the compartment containing 50 ml of dissolution medium 
(PBS pH 7.4), which was stirred in a water bath shaker at 100 rpm 
and maintained at 37°C±0.5°C. At predetermined time intervals, the 
requisite quantity (1 mL) of samples were withdrawn and analyzed by 
RP-HPLC method. Equal quantity of fresh releasing media was added to 
maintain the definite volume [6].
Stability studies
The fabricated formulation was subjected to accelerated stability 
studies as per International Conference on Harmonization (ICH) 
guidelines to evaluate the effect on stress conditions. NTG-loaded 
EC nanoparticles were packed in 0.044 mm delaminated aluminum 
foil and subjected to elevated temperature and humidity conditions 
of 40°C±2°C/75%±5% RH (accelerated), 30°C±2°C/65%±5% RH 
(intermediate), and also 25°C±2°C/60%±5% RH (long term condition). 
Samples were withdrawn at the end of 0, 3, and 6 months and evaluated 
for physical properties of the nanoparticles by particle size, zeta 
potential, drug content, and drug release rate [7,13].
RESULTS AND DISCUSSION
Preparation of NTG nanoparticles
The NTG-loaded EC nanoparticles were successfully prepared by solvent 
evaporation technique. This method was simple and reproducible 
for the preparation of NTG loaded EC nanoparticles. In this method, 
the drug and polymer were dissolved in organic solvent mixture and 
the organic phase was mixed slowly to aqueous phase containing 
surfactant with constant stirring by using mechanical stirrer to form 
the nanoparticles and to evaporate the organic phase. The solution was 
centrifuged and sediments were collected and washed with deionized 
water three times to remove any un-entrapped drugs. The sediment 
was freeze-dried to get the powdered products.
Determination of particle size and zeta potential
The hydrodynamic diameter of the prepared nanoparticles was found 
to be ~172 nm (Fig. 2). The PI of the particles was 0.341, which indicate 
the prepared nanoparticles were mono dispersed.
Stability of the nanoparticles is indicated by zeta potential. No matter 
what is the charge type, higher the magnitude, higher the stability. Zeta 
potential of the nanoparticles showed higher stability with a value of 
−15.6 mV (Fig. 3). Pure EC nanoparticles are expected to have a high 
Fig. 2: Particle size distribution of optimized nateglinide-loaded 
ethyl cellulose nanoparticles formulation
Fig. 3: Zeta potential of optimized nateglinide-loaded ethyl 
cellulose nanoparticles formulation
Asian J Pharm Clin Res, Vol 8, Issue 6, 2015, 93-96
 Gopi and Kannan 
95
negative zeta potential due to the presence of residual stabilizers on the 
nanoparticles surface. A shield could have been created between the 
nanoparticles surface and the surrounding medium due to the presence 
of the residual stabilizer on the nanoparticles surface. In addition, the 
stabilizers could mask the available charged group found on the particle 
surface [9].
Determination of DL and drug EE
The drug content and drug EE of the NTG-loaded EC nanoparticles 
was determined by the RP-HPLC method. The respective values were 
calculated from a standard curve prepared under the same experimental 
parameters. The DL and drug EE of the NTG-loaded EC nanoparticles 
were found to be 14.30%±0.27% and 72.19%±0.24%, respectively, all 
the measures were carried out in triplicate (n=3).
SEM analysis
SEM analysis was carried out for optimized NTG-loaded EC 
nanoparticles formulation to examine its shape and surface morphology 
(Fig. 4). The SEM images showed that smooth surface of the particles 
with distinct, uniform, and spherical structure and it indicates that the 
formulation method was efficient. The smooth surface observed in the 
images reveals complete removal of the solvent from the formulated 
nanoparticles [14].
Drug release studies
The percentage of drug release from NTG-loaded EC nanoparticles was 
studied as a function of time in in vitro condition. The drug release study 
was performed by using the dialysis bag diffusion method. The percentage 
amount of drug released from NTG-loaded EC nanoparticles formulations 
was depicted in Fig. 5. The formulation shows a significant and sustained 
release (up to 86.21% in 12 hrs) of NTG in nanoparticles form as compared 
to the marketed conventional formulation. About 93.42% of the drug was 
released from the marketed formulation after 1.5 hrs. Thus, it is evident 
that nanoparticles have a small initial burst and sustained release than 
that of the marketed formulation. The sustained release nature is thought 
to be mainly because of the 1:5 ratio of polymer and that of the drug. EE 
72.19% obtained was expected due to the ratio 1:5 again.
The release of drug from the polymer matrix was based on diffusion 
mechanisms. EC is widely used to control the dissolution rate of 
drugs from sustained release preparations. EC possess plastic and 
hydrophobic property, drug particles present in the surface of matrix 
is initially released into the surrounding media generating many pores 
and cracks which facilitate further release of drug and EC did not 
change its drug retaining activity due to the change of pH. The increase 
in drug content in the particles influence the absolute release profiles 
of the drug, in such a way that, it increases the induction period and the 
cumulative amount of drug released at any given point of time. The drug 
content which is closer to the surface of the nanoparticles is responsible 
for an increased initial burst and the drug in the core of nanoparticles is 
responsible for a prolonged drug release from the polymer [4].
Stability study
NTG-loaded EC nanoparticles were subjected to stability studies as 
per ICH guidelines. Stability studies according to ICH guidelines 
revealed that the fabricated nanoparticles were stable at the end of 
6 months in all the test conditions (Table 1). No significant changes in 
particle size, zeta potential, drug content, and drug release rate were 
observed after the end of 0, 3, and 6 months and found identical in 
stability studies.
CONCLUSION
NTG-loaded EC nanoparticles were prepared by solvent evaporation 
method. By using a mixture of protecting excipients such as EC and 
polyvinyl alcohol more stable nanoparticles could be prepared. The 
formulation shows mean particles size distribution of ~172 nm. The 
SEM images showed a smooth surface of the particles with round 
structure and the optimum EE of 72.19%±0.24%. The sustained 
drug release was found to be 86.21% in 12 hrs. Thus, NTG-loaded 
EC nanoparticles could reduce dosing frequency and sustained 
release leading to improve patient compliance. These developed 
nanoparticles can be safer and promising agents for rational drug 
delivery system for the treatment of disease like type II diabetes 
mellitus.
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Table 1: Stability studies of optimized NTG‑loaded EC nanoparticles formulation





























NTG: Nateglinide, EC: Ethyl cellulose
Fig. 4: Scanning electron microscopy images of optimized 
nateglinide-loaded ethyl cellulose nanoparticles formulation 
taken at 3.0 kV 50,000 magnifications
Fig. 5: Comparative cumulative percentage drug release plot for 
nateglinide marketed tablets (Glinate® 60 mg) and optimized 
nateglinide -loaded ethyl cellulose nanoparticles formulation
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